Clinical applications of interleukin-2.
| dc.contributor.author | Von Rohr, A | |
| dc.contributor.author | Thatcher, Nick | |
| dc.date.accessioned | 2010-07-15T09:07:16Z | |
| dc.date.available | 2010-07-15T09:07:16Z | |
| dc.date.issued | 1992 | |
| dc.identifier.citation | Clinical applications of interleukin-2. 1992, 4 (3):229-46 Prog Growth Factor Res | en |
| dc.identifier.issn | 0955-2235 | |
| dc.identifier.pmid | 1307490 | |
| dc.identifier.uri | http://hdl.handle.net/10541/107696 | |
| dc.description.abstract | Interleukin-2 (IL-2) is a cytokine with potent immunomodulating properties which has shown considerable antitumour activity in preclinical models. In clinical trials, the effects of IL-2 given by various routes and schedules have been investigated. IL-2 has been administered either as single drug or in combination with other cytokines and immunomodulating agents, chemo therapeutic agents, or reinfusions of ex vivo activated autologous cytotoxic effector cells. The results of published clinical studies with IL-2 based immunotherapy are reviewed in this paper. | |
| dc.language.iso | en | en |
| dc.subject | Tumour-Infiltrating Lymphocytes | en |
| dc.subject.mesh | Clinical Trials as Topic | |
| dc.subject.mesh | Combined Modality Therapy | |
| dc.subject.mesh | Cytokines | |
| dc.subject.mesh | Dose-Response Relationship, Drug | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Immunotherapy, Adoptive | |
| dc.subject.mesh | Interleukin-2 | |
| dc.subject.mesh | Killer Cells, Lymphokine-Activated | |
| dc.subject.mesh | Lymphocytes, Tumor-Infiltrating | |
| dc.title | Clinical applications of interleukin-2. | en |
| dc.type | Article | en |
| dc.contributor.department | CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K. | en |
| dc.identifier.journal | Progress in Growth Factor Research | en |
| html.description.abstract | Interleukin-2 (IL-2) is a cytokine with potent immunomodulating properties which has shown considerable antitumour activity in preclinical models. In clinical trials, the effects of IL-2 given by various routes and schedules have been investigated. IL-2 has been administered either as single drug or in combination with other cytokines and immunomodulating agents, chemo therapeutic agents, or reinfusions of ex vivo activated autologous cytotoxic effector cells. The results of published clinical studies with IL-2 based immunotherapy are reviewed in this paper. |